1.45

1,11 لِهِ,ا 152

: 12

Harris . 1,57

ı sa



Docket Number 4-30944A/C1 FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

751039472 Express Mail Label Number

OCT 2 5 2001

Date of Deposit

Address to: Assistant Commissioner for Patents

Box Patent Application Washington, DC 20231

UTILITY PATENT APPLICATION TRANSMITTAL AND FEE SHEET

Transmitted herewith for filing under 37 CFR §1.53(b) (1) is a **continuation** of prior Application No. PCT/EP00/03688, filed April 25, 2000.

Applicant (or identifier): FRANCE ET AL.

Title:

USE OF 2,4-DIAMINO-3-HYDROXYCARBOXYLIC ACID

DERIVATIVES AS PROTEASOME INHIBITORS

Enclosed are:

1.	\boxtimes	Specification (Including Claims and Abstract) - 35 pages						
2. 3.		Drawings - sheets Unexecuted Declaration and Power of Attorney (copy)						
4. 5.	Ш	Microfiche Computer Program (appendix) Nucleotide and/or Amino Acid Sequence Submission						
		Computer Readable Copy Paper Copy						
_		Statement Verifying Identity of Above Copies						
6. 7.	H	Preliminary Amendment Assignment Papers (Cover Sheet & Document(s))						
8.	H	English Translation of						
9.	百	Information Disclosure Statement						
10.		Certified Copy of Priority Document(s)						
11.	\boxtimes	Return Receipt Postcard						
12.	\boxtimes	Other: Bib Data Sheet						
Filing fee calculation:								
		ore calculating the filing fee, please enter the enclosed Preliminary Amendment. ore calculating the filing fee, please cancel claims						

Basic Fili	asic Filing Fee										
Multiple !	Multiple Dependent Claim Fee (\$ 280)										
Foreign L	oreign Language Surcharge (\$ 900)										
	For	Number Filed		Number Extra			Rate				
Extra Claims	Total Claims	15	-20	0	x	\$	18	=	\$		
	Independent Claims	2	-3	0	х	\$	84	=	\$		
TOTAL FILING FEE											

Please charge Deposit Account No. 19-0134 in the name of Novartis Corporation in the amount of \$740. An additional copy of this paper is enclosed. The Commissioner is hereby authorized to charge any additional fees under 37 CFR §1.16 and §1.17 which may be required in connection with this application, or credit any overpayment, to Deposit Account No. 19-0134 in the name of Novartis Corporation.

Please address all correspondence to the address associated with Customer No. 001095, which is currently:

Thomas Hoxie Novartis Corporation Patent and Trademark Dept. 564 Morris Avenue Summit, NJ 07901-1027

Date: OCT 2 5 2001

Please direct all telephone calls to the undersigned at the number given below, and all telefaxes to (908) 522-6955.

Respectfully submitted,

George R. Dohmann Attorney for Applicants

Reg. No. 33,593

Tel. No. (908) 522-6922